Double-blinded, Placebo-controlled Randomized Study Evaluating the Efficacy of Risedronate to Prevent the Loss of Bone Mineral Density in Non-metastatic Prostate Cancer Patients Undergoing Radiotherapy Plus 2-3 Years of Androgen Ablation Therapy
Open Access
- 1 October 2011
- journal article
- abstracts
- Published by Elsevier BV in International Journal of Radiation Oncology*Biology*Physics
- Vol. 81 (2), S42
- https://doi.org/10.1016/j.ijrobp.2011.06.086